Skip to main content

Articles

Original Research

The Prevalence and Determinants of Controlled Substance Discrepancies in a Level I Trauma Hospital

Stakeholder Perspective

Dramatic Increase in Misuse of Controlled Substances a Concern for All Stakeholders

Original Research

Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation

Stakeholder Perspective

Continuing Challenges in COPD Management, Despite Its Prevalence and High Economic Burden

Practice Management

Increased Burden of Healthcare Utilization and Cost Associated with Opioid-Related Constipation Among Patients with Noncancer Pain

Stakeholder Perspective

Can Improved Management of Opioid-Induced Constipation Mitigate the Associated Costs?

Conference Highlights AMCP

Implications of Real-World Data and Pharmacoeconomics for Managed Care

Practice Management

Will the PCSK9 Inhibitors Be Employers’ “Line in the Sand”?

In the News, Lung Cancer, Oncology

New Data Show Osimertinib Effective as First-Line Treatment of NSCLC with EGFR Mutation

Lilly Ostrovsky

Atezolizumab First PD-L1 Inhibitor Approved by the FDA for Advanced or Metastatic Urothelial Cancer

Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas

Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder

Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Page 111 of 244
Results 1101 - 1110 of 2436